Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine

October 09, 2017

WHAT:

Despite remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine likely will be necessary to achieve a durable end to the HIV/AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Theoretically, effective global implementation of existing HIV treatment and prevention tools could end the HIV/AIDS pandemic. Antiretroviral therapy that suppresses HIV both benefits the health of those living with HIV and prevents viral transmission to their HIV-negative sexual partners. Additionally, strategies such as pre-exposure prophylaxis (PrEP) can effectively prevent HIV acquisition among people at high risk for infection.

However, from a practical standpoint, ending the HIV/AIDS pandemic without a vaccine is unlikely. Despite extraordinary progress in implementing HIV testing and treatment, substantial gaps remain. Globally, more than 17 million people living with HIV are not receiving antiretroviral therapy. This is compounded by the continuing high rate of new infections, an estimated 1.8 million worldwide in 2016 alone. Modeling studies have suggested that the wide geographic dispersion of people, especially in certain rural areas, would make it extremely difficult to reach all those who need HIV treatment and prevention services. In addition, the economic resources needed to leverage HIV treatment and prevention across the globe continually increase as people become newly infected.

Dr. Fauci writes that even a modestly effective HIV vaccine could substantially slow the pandemic, if deployed alongside current treatment and prevention efforts. Because the immune system mounts an inadequate protective response against HIV, an HIV vaccine most likely will not be as effective as proven vaccines used to control or end global outbreaks, such as yellow fever and polio vaccines, which are nearly 100 percent effective. According to modeling studies, if current HIV treatment and prevention efforts are sustained and an HIV vaccine that is at least 50 percent effective is developed and deployed, the pandemic could be curbed.

It is critical to continue and accelerate a robust research effort to develop an HIV vaccine that is at least moderately effective, while also aggressively scaling up the implementation of current treatment and prevention tools, Dr. Fauci concludes.
-end-
ARTICLE:

AS Fauci. An HIV vaccine is essential for ending the HIV/AIDS pandemic. Journal of the American Medical Association DOI: 10.1001/jama.2017.13505 (2017).

WHO:

NIAID Director Anthony S. Fauci, M.D., is available to comment.

CONTACT:

To schedule interviews, please contact Hillary Hoffman, (301) 402-1663, hillary.hoffman@nih.gov.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.